Metastatic Breast Cancer (Canada) Top 10 Priorities

  1. What biomarkers or intrinsic features of the tumour can be used to identify response to specific treatments and dosing schedules?
  2. What is the role of immunotherapy for metastatic breast cancer?
  3. How can treatment resistance be delayed, and minimized?
  4. What causes (i.e. cellular, genomic changes) breast cancer cells to metastasize, and what changes allow them to penetrate the blood-brain barrier?
  5. What is the right sequence of therapy in metastatic breast cancer?
  6. Does local therapy (radiation or surgery to sites of metastatic disease) improve survival outcomes in metastatic breast cancer?
  7. Is continuous treatment with systemic therapy (including HER2-targeted therapy and chemotherapy) better than intermittent treatment?
  8. Does early palliative care improve outcomes for metastatic breast cancer patients?
  9. What are the best methods of education for patients around treatment options and decision making that can lead to improved patient outcomes?
  10. Can safer, more accurate methods, including blood tests of detecting spread of disease (including following curative intent treatment) be developed?